NCT04736758View on ClinicalTrials.gov

A Clinical Study on the Safety and Efficacy of GP681 Tablets in the Treatment of Uncomplicated Acute Influenza

PHASE2CompletedINTERVENTIONAL
Enrollment

216

Participants

Timeline

Start Date

January 8, 2021

Primary Completion Date

December 18, 2021

Study Completion Date

December 18, 2021

Conditions
Influenza
Interventions
DRUG

GP681 tablet

influenza subjects is randomized 1:1:1 into GP681 tablet 40mg group,GP681 tablet 20mg group and Placebo group,with 72 patients in each group.subjects is given with GP681 tablet or GP681 Simulant only once to treat influenza.

DRUG

GP681 Simulant

influenza subjects is randomized 1:1:1 into GP681 tablet 40mg group,GP681 tablet 20mg group and Placebo group,with 72 patients in each group.subjects is given with GP681 tablet or GP681 Simulant only once to treat influenza.

Trial Locations (1)

330006

The First Affiliated Hospital of Nanchang University, Nanchang

Sponsors
All Listed Sponsors
lead

Jiangxi Qingfeng Pharmaceutical Co. Ltd.

INDUSTRY